Reduction of Purkinje cell pathology in SCA1 transgenic mice by p53 deletion

Neurobiology of Disease

Volumn 8, Issue 6, 2001, Pages 974-981

  Shahbazian, Mona D ^a   Orr, Harry T ^b   Zoghbi, Huda Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYGLUTAMINE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DENDRITE; GENE DELETION; HETEROTOPIA; MOTOR COORDINATION; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PURKINJE CELL; SPINOCEREBELLAR DEGENERATION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

EID: 0035664111     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2001.0444     Document Type: Article

References (33)

1. Ubiquitin, cellular inclusions and their role in neurodegeneration
2. SCA1 transgenic mice: A model for neurodegeneration caused by an expanded CAG trinucleotide repeat
3. Evidence for proteasome involvement in polyglutamine disease: Localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro
4. Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations
5. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
6. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice
7. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
8. Identification of genes that modify ataxin-1-induced neurodegeneration
9. The function of PML in p53-dependent apoptosis
10. A role for the tumour suppressor gene p53 in regulating neuronal apoptosis
11. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons
12. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release
13. Absence of p53: No effect in a transgenic mouse model of familial amyotrophic lateral sclerosis
14. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis
15. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1
16. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death
17. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
18. Polyglutamine disease and neuronal cell death
19. Motor neuron cell death in a mouse model of FALS is not mediated by the p53 cell survival regulator
20. Caspase-8 is required for cell death induced by expanded polyglutamine repeats
21. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures
22. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
23. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone
24. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression
25. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells
26. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
27. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila
28. The role of free radicals and p53 in neuron apoptosis in vivo
29. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
30. Evidence for p53-mediated modulation of neuronal viability
31. The transcriptional role of PML and the nuclear body
32. Spinocerebellar ataxia type 1
33. Glutamine repeats and neurodegeneration